

## SEMINAR OVERVIEW

This seminar series will provide updates on the diagnosis and treatment of chronic liver disease with a strong focus on patient care and symptom management. Teams of local, hepatology experts (physicians and advanced-practice providers) will deliver an interdisciplinary, team-based approach in a classroom setting that stresses interaction between participants and faculty.

To lower the barriers to participation and increase access, the program will be offered on Saturdays in twelve cities throughout the country beginning in December 2018. See the calendar of programs.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

**Primary Biliary Cholangitis (PBC)** is an old disease but one that is experiencing some major changes. A new treatment, Obetacholic Acid (OCA), the first new drug for the disease in 20 years, is a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

**Non-Alcoholic Steatohepatitis (NASH)** is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers and other non-invasive tests to help diagnose it and promising therapies coming out of research trials. Also there are new breakthroughs in the treatment of Thrombocytopenia and NAFLD.

**End Stage Liver Disease (ESLD)** is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

**Hepatocellular Carcinoma (HCC)** is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies to treat and/or reduce tumor size.

# 2018-2019

## Emerging Therapies for PBC, NASH, ESLD and HCC

An Evidence-Based Seminar Focused on Chronic Liver Diseases

Non-Profit Org.  
U.S. Postage  
Paid  
Louisville, Ky.  
Permit No. 769

UNIVERSITY OF  
**LOUISVILLE**  
Continuing Medical  
Education &  
Professional Development  
University of Louisville  
Louisville, KY 40292

### LOCATIONS & FACULTY

#### San Diego, CA

Saturday December 1, 2018  
Marriott La Jolla Hotel

#### Paul Pockros, MD

Scripps Clinic

#### Robert Gish, MD

Stanford University School of Medicine

#### Lisa Richards, PA-C

University of California, San Diego  
Medical Center

#### Seattle, WA

Saturday December 8, 2018  
Seattle Renaissance Hotel

#### Kris Kowdley, MD

Swedish Medical Center

#### Charles Landis, MD, PhD

University of Washington Medical Center

#### Paula C. Cox-North, PhD, APRN

Harborview Medical Center

#### Louisville, KY

Saturday February 9, 2019

University of Louisville, Clinical &

Translational Research Bldg.

#### Craig McClain, MD

University of Louisville School of Medicine

#### Matthew Cave, MD

University of Louisville School of Medicine

#### Ashutosh Barve, MD, PhD

University of Louisville School of Medicine

#### Barbara Cave, APRN, FNP-BC

Jewish Hospital Hepatitis C Center

#### St. Louis, MO

Saturday, February 23, 2019  
Sheraton Westport Chalet Hotel

#### Bruce Bacon, MD

St. Louis University School of Medicine

#### Adrian Di Bisceglie, MD

St. Louis University School of Medicine

#### Alexa Fider-Whyte, PA-C

St. Louis University School of Medicine

#### Dallas, TX

Saturday, March 2, 2019  
Embassy Suites Dallas Park Central

#### Stephan Harrison, MD

Pinnacle Clinical Research

#### Jacqueline O'Leary, MD

Baylor University Medical Center

#### Jordan Mayberry, MPAS, PA-C

UT Southwestern Medical Center

# Don't Miss Out On This National Program Coming To A City Near You!

San Diego, CA  
December 1



Seattle, WA  
December 8



Louisville, KY  
February 9



St. Louis, MO  
February 23



Dallas, TX  
March 2



## PROGRAM HIGHLIGHTS

The conference will focus on the challenges of: Diagnosis and treatment of chronic liver disease; current and emerging drug and surgical therapies and incorporating new knowledge to improve patient outcomes

- ▶ Updated content based on the latest medical guidelines and clinical trial results
- ▶ Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs
- ▶ Interactive format that includes practical patient case review, small group discussion and the use of Audience Response technology to gauge opinion and build consensus
- ▶ Teams of local experts, comprised of physicians and advanced-practice clinicians, providing an interdisciplinary, team approach to treatment
- ▶ Participants can receive up to **6.0 AMA PRA Category 1 Credits™** or up to 7.1 nursing education credits

## WHO SHOULD ATTEND

**This program is especially developed for Hepatologists, Gastroenterologists, Internists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.**

These are the providers who are primarily tasked with caring for patients with chronic liver disease, both in the hospital and in the outpatient setting.

## FUTURE EVENTS

**Palo Alto, CA, March 16 | New Orleans, LA, March 30  
Pasadena, CA, April 27 | Raleigh, NC, May 4  
Detroit, MI, June 1 | Washington, DC, June 8  
Denver, CO, June 22**

# SCHEDULE

|          |  |
|----------|--|
| 7:30 am  | <b>Registration, Continental Breakfast &amp; View Exhibits</b>   |
| 8:00 am  | <b>Welcome and Pre-Test</b>  |
| 8:20 am  | <b>End Stage Liver Disease: Treatment, Managing Complications and Transplant</b> <ul style="list-style-type: none"><li>▶ Staging, workup, and diagnosis of cirrhosis</li><li>▶ Medical care of the patient with end stage liver disease</li></ul> <b>Liver Transplantation</b> <ul style="list-style-type: none"><li>▶ Listing criteria, MELD scores, exceptions and the transplant process</li></ul> <b>Case Study 1</b> - Cirrhosis and Encephalopathy |
| 9:20 am  | <b>Hepatocellular Carcinoma</b> <ul style="list-style-type: none"><li>▶ Screening diagnostic serum assays and imaging tests</li><li>▶ Diagnosis without histology</li><li>▶ Treatment and management options: Ablation, TACE and Surgery</li></ul>   |
| 10:00 am | <b>Break &amp; View Exhibits</b>   |
| 10:15 am | <b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"><li>▶ Current FDA-approved therapies</li><li>▶ New chemotherapy regimens in development and testing</li><li>▶ Immunotherapy as the new MoA for HCC</li></ul> <b>Case Study 2</b> - Diagnosis and Treatment of Hepatocellular Carcinoma   |
| 11:00 am | <b>Primary Sclerosing Cholangitis (PSC)</b> <ul style="list-style-type: none"><li>▶ Epidemiology</li><li>▶ Ursodiol and Antibiotic Treatments</li><li>▶ Predicting Outcomes and Improving Survival</li></ul>   |
| 11:25 am | <b>New Treatments for Primary Biliary Cholangitis (PBC)</b> <ul style="list-style-type: none"><li>▶ Causes and Markers of PBC</li><li>▶ Treatment Management</li><li>▶ Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li></ul>  |
| 12:00 pm | <b>Luncheon and Educational Session</b>  |
| 12:45 pm | <b>Coffee and Dessert &amp; View Exhibits</b>  |
| 1:00 pm  | <b>The Best Use of Non-Invasive Imaging for Fibrosis Assessment</b> <ul style="list-style-type: none"><li>▶ Technologies, Procedures and Outcomes</li></ul>  |
| 1:30 pm  | <b>NAFLD, LAL-D and NASH</b> <ul style="list-style-type: none"><li>▶ Epidemiology, Demographics and Diagnosis</li><li>▶ Treatment options for Thrombocytopenia; including alternatives to platelet transfusion.</li><li>▶ Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease</li></ul>  |
| 2:15 pm  | <b>Break &amp; View Exhibits</b>   |
| 2:30 pm  | <b>NASH Treatments in Development</b> <ul style="list-style-type: none"><li>▶ Current therapies for NASH</li><li>▶ Life style change as a therapy</li><li>▶ Drugs in clinical development for NASH</li></ul> <b>Case Study 3</b> - NASH Diagnosis and Treatment  |
| 3:30 pm  | <b>Post Test and Adjourn at 3:45pm</b>   |

## EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- ▶ Summarize the causes of chronic liver disease and hepatic encephalopathy
- ▶ Comprehend the complexities of organ transplant procedures and waitlists
- ▶ Review the current therapies for PBC and clinical approaches for PSC
- ▶ Learn about diagnostic tests for NASH that may soon be in daily use
- ▶ Discuss the importance of liver biopsy for assessment of liver disease as well as less invasive tools and procedures
- ▶ Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number
- ▶ Discover why Immunotherapy is the new Method of Action for Hepatocellular Carcinoma
- ▶ Discuss treatment options for thrombocytopenia; including therapeutic alternatives to platelet transfusion
- ▶ Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management processes and clinical outcomes.
- ▶ Utilize current clinical cases to improve diagnostic and treatment skills

## COURSE DIRECTORS

### Paul Pockros, MD, FAGG

Director, Liver Disease Center  
Scripps Clinic

### Catherine Fernet, MD

Medical Director for Liver Transplantation  
Scripps Center for Organ and Cell  
Transplantation

## Registration Information

|                                      | Early Registration | Regular Registration |
|--------------------------------------|--------------------|----------------------|
| Physicians and Clinical Pharmacists  | \$95               | \$115                |
| Nurses, Nurse Practitioners and PA's | \$70               | \$90                 |
| Medical Residents & Fellows          | \$60               | \$80                 |

### To Register & For More Information: <http://bit.ly/liver18-19>

Or call: University of Louisville CME & PD (502) 852-5329

**Early Registration** ends Tuesday prior to program date.

**Regular Registration** begins Wednesday prior to through program date.

**Cancellation Policy** - Requests for cancellation must be submitted to [cmepd@louisville.edu](mailto:cmepd@louisville.edu) at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

## ACCREDITATION

### Joint Provider Statement



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

### Designation Statement

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)<sup>™</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners & Physician Assistants** - AANP and AAPA accept Category I credit from **AMA PRA Category 1 Credit(s)<sup>™</sup>** organizations accredited by ACCME.

## SPONSORS



The mission of the **University of Louisville** Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>



**The SC Liver Research Consortium (SCLRC)** is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to team research sponsors and SCLRC's over 90 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit [www.scliver.com](http://www.scliver.com)

### DISCLOSURE

#### Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

#### Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.